Navigation Links
Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Date:11/11/2009

NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) has been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The clinical data to be presented demonstrates the potential safety and efficacy of KRX-0401 in the treatment of patients with relapsed/refractory multiple myeloma.

    Details on the Abstract selected for poster presentation are as follows:

    Abstract #:         1869

    TITLE:  Perifosine in Combination with Bortezomib and Dexamethasone
    Extends Progression-Free Survival and Overall Survival in
    Relapsed/Refractory Multiple Myeloma Patients Previously Treated with
    Bortezomib: Updated Phase I/II Trial Results

    Lead Author:        Paul Richardson, MD

    Session Name:       Myeloma - Therapy, excluding Transplantation Poster I

    Date:               Saturday, December 5, 2009

    Presentation Time:  5:30 PM - 7:30 PM

    Location:           Ernest N. Morial Convention Center, Hall E

    Poster Board no.:   I-891

This abstract became available for viewing yesterday on the American Society of Hematology website (www.hematology.org). At the time of the abstract submission in mid-August 2009, there were 84 patients enrolled on study, of which 73 were evaluable for efficacy and are reported on within the abstract. Updated efficacy (response rate, time-to-progression and survival) and safety analyses, as of mid-November 2009, will be presented at the conference.

A copy of the above referenced abstract can be viewed online through the ASH website,

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
4. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
5. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
6. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
(Date:7/24/2014)... and MARSEILLE, France , July 24, ... global license from University of Tokyo enables development of ... gene panels, for blood cancers  Mutations of ... favorable prognosis for patients with bone marrow disorders known ... developing companion diagnostics to guide treatment with new anti-cancer ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14
(Date:7/26/2014)... 2014 “BRIC Sinuscopes Market Outlook to ... market. The report provides value, in millions of US ... dollars) within market segments – Rigid Non-Video Sinuscopes. , ... data for each of these market categories, and global ... and news and deals related to the Sinuscopes market ...
(Date:7/26/2014)... Dallas, TX (PRWEB) July 26, 2014 ... sclerosis or encephalomyelitis disseminata, is an inflammatory disease ... in the brain and spinal cord are damaged. ... the nervous system to communicate, resulting in a ... mental, and sometimes psychiatric problems. Multiple sclerosis takes ...
(Date:7/26/2014)... 26, 2014 According to the Metabolic ... is a comprehensive bodybuilding program that helps men lose ... anabolic steroids . The program also instructs men how ... , Vkool reveals in its review that this ... can help men get ripped and jacked at the ...
(Date:7/25/2014)... 26, 2014 Dental Perfection, a Derby ... services including general dentistry, clear braces and much more, ... this year in Derby. The new practice, which is ... Medical Centre in Littleover, Derby. Patients may already pre-register ... The new dental practice, which is headed by Invisalign ...
(Date:7/25/2014)... 26, 2014 According to a ... by Product (vibration monitoring, thermography, ultrasound emission, lubricating ... Component, Application and Geography - Global Forecast to ... health monitoring market is expected to reach $2.50 ... 2020. , Browse 117 market data Tables and ...
Breaking Medicine News(10 mins):Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4
... According to a study published in the October issue of ... phyllodes tumors rare breast malignancies accounting for 0.5 to ... more prevalent in Hispanic patients. Population-based estimates indicate that the ... women, with the highest frequencies in Hispanic women. Previous ...
... Whistleblowing incidents can have a serious, long-term impact on ... a responsibility to provide them with the support they ... of the Journal of Clinical Nursing . ... nurses who had been reported by whistleblowers. ...
... cancer survivors in Northern Ireland suffer from physical and ... according to new research from Macmillan Cancer Support and ... its kind in Northern Ireland, also found cancer survivors ... services than the general population. The research highlighted ...
... partnership with the American Society for Radiation Oncology (ASTRO), ... recognized 39 educators with the 2011 Educator of the ... the Year Award to recognize outstanding teachers and mentors ... programs were given the opportunity to select one faculty ...
... By Steven Reinberg HealthDay Reporter , MONDAY, Oct. ... as multivitamins, minerals and folic acid may actually raise the ... new study suggests. Dietary supplements are widely used in ... disease. However, the long-term health consequences of many compounds are ...
... conclusions can be drawn about the effect of recent reforms ... coalition government,s proposals to extend competition, warn experts on ... Skellern at the London School of Economics and Political Science ... of hospital competition on quality of care within the English ...
Cached Medicine News:Health News:Hispanic women have higher incidence of rare breast tumor 2Health News:Greater support is needed to tackle the serious emotional consequences of whistleblowing 2Health News:Greater support is needed to tackle the serious emotional consequences of whistleblowing 3Health News:Almost half of cancer survivors have ill health in later years 2Health News:ARRO honors 39 with Educator of the Year Award 2Health News:Dietary Supplements May Harm Older Women: Study 2Health News:Dietary Supplements May Harm Older Women: Study 3Health News:Experts question merits of extending competition to improve hospital care 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: